

**I. Listing of Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-8. (Cancelled)

9. (Currently Amended) A method of treating a condition which can be alleviated by ~~agonism of an EP<sub>2</sub> receptor~~ agonist, which method comprises administering to a patient in need of treatment an effective amount of (1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or pharmaceutically acceptable salt thereof or (1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof. ~~a compound according to claim 1, or a pharmaceutically acceptable salt thereof.~~

10. (Original) The method according to claim 9, wherein the condition alleviated by agonism of an EP<sub>2</sub> receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.

Claims 11-15. (Cancelled).

16. (Currently Amended) The method according to claim 9 wherein the condition is A method of treating a psoriasis, which method comprises administering to a patient in need of treatment an effective amount of an EP<sub>2</sub> receptor agonist, or a pharmaceutically acceptable salt thereof.

17. (Currently Amended) The method according to claim 9 wherein the condition is A method of treating a an inflammatory lung disease., which method comprises administering to a patient in need of treatment an effective amount of an EP<sub>2</sub> receptor agonist, or a pharmaceutically acceptable salt thereof.

Claim 18. (Cancelled)

19. (New) The method of claim 9 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, osteoporosis, asthma, allergy, bone disease, fracture repair, infertility, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer and renal disease.

20. (New) The method of claim 19 wherein the condition is selected from a group consisting of psoriasis, pre-term labour, glaucoma, and an inflammatory lung disease; and the EP<sub>2</sub> receptor agonist is (1R,2S)-2-[4-(1-(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.

21. (New) The method of claim 19 wherein the condition is selected from a group consisting of psoriasis, dysmenorrhoea, pre-term labour, glaucoma, and an inflammatory lung disease; and the EP<sub>2</sub> receptor agonist is (1R,2S)-2-[4-(1-(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid or a pharmaceutically acceptable salt thereof.